--(BUSINESS WIRE)----Merck & Co., Inc. (NYSE: MRK - News) Merck & Co., Inc. will host a conference call for pharmaceutical analysts and U.S. reporters and editors to discuss Phase III efficacy and safety data on JANUVIA, an investigational oral, once-daily treatment for type 2 diabetes. These data will be presented for the first time at the American Diabetes Association annual scientific sessions in Washington, D.C., from June 9 to 13, 2006.
